A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856 will be flexibly dosed for 8 weeks.

Trial Locations (25)

20877

CBH Health, Gaithersburg

28211

New Hope Clinical Research, Charlotte

28601

Clinical Trials of America, LLC, Hickory

30318

Advanced Discovery Research LLC, Atlanta

30331

Atlanta Center for Medical Research, Atlanta

30358

Atlanta Behavioral Research, Atlanta

32803

Nova Psychiatry, Inc., Orlando

33021

Larkin Behavioral Health Services, Hollywood

33122

Premier Clinical Research Institute, Inc., Miami

33135

Wellness Research Center, Miami

44125

Charak Clinical Research Center, Garfield Heights

60640

Uptown Research, Chicago

63128

PsychCare Consultants Research, St Louis

75080

Pillar Clinical Research, LLC, Richardson

89102

IMA Clinical Research, Las Vegas

90230

ProScience Research Group, Culver City

90502

Cenexel CNS Research, Torrance

90706

Clinical Innovations Inc., Bellflower

91945

Synergy San Diego, Lemon Grove

92071

CMB Clinical Trials, Santee

92102

California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego

92506

Clinical Innovations, Inc, Riverside

92805

Advanced Research Center, Inc., Anaheim

92845

Collaborative Neuroscience Research, LLC, Garden Grove

08009

Hassman Research Institute, Berlin

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY